{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:48:23Z","timestamp":1792075703965,"version":"4.4.0"},"reference-count":75,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Form Res"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n In recent years, the availability of digital therapeutic apps in medicine, digital therapeutics (DTx), has significantly increased. To evaluate the therapeutic efficacy of DTx, an increasing number of scientific studies have been conducted in this field. Several authors have pointed out that a standardized approach to DTx evaluation is relevant to improving the comparability of apps in the future. Currently, it is unclear how study authors proceed when selecting outcomes and measurement methods (O&M) for DTx studies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary aim of this study was to investigate how study authors currently select O&M in DTx studies, specifically for applications delivered in the form of apps. The secondary objectives were to collect suggestions for improving the comparability of DTx apps and studies in the future and to examine whether core outcome sets (COS) could represent a possible solution for enhancing comparability.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study was based on 19 semistructured interviews. All interview partners had prior experience in planning and conducting DTx studies. The interviews were conducted between August 2024 and November 2024. Subsequently, qualitative data analysis was performed according to Kuckartz and R\u00e4diker using a deductive-inductive research approach.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The results of this study showed that the methodological approach for selecting O&M in DTx studies was primarily based on research, as well as on personal prior experience and individual ideas. Interview participants indicated that when selecting O&M, they particularly focused on aspects such as scientific quality criteria or practical implementation and feasibility. A suggestion for achieving better comparability of DTx studies in the future was to use standardized O&M per therapeutic indication area. Almost all interviewees considered COS to be a suitable approach for improving the comparability of DTx and associated studies. However, we also identified critical perspectives that questioned their application.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Across professional groups, both commonalities and differences were observed in methodological approaches as well as in the selection of O&M in DTx studies. To improve the comparability of DTx interventions and trials, several approaches have been developed, for example, through the use of guidance frameworks, artificial intelligence programs, or the establishment of COS. However, further research is warranted to advance this field.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/86437","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:41:25Z","timestamp":1792075285000},"page":"e86437-e86437","source":"Crossref","is-referenced-by-count":0,"title":["Selection of Outcomes and Measurement Methods in Clinical Trials for Digital Therapeutics: Qualitative Analysis"],"prefix":"10.2196","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6062-5341","authenticated-orcid":false,"given":"Johannes","family":"Mahlmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9790-6049","authenticated-orcid":false,"given":"Anne","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7473-6371","authenticated-orcid":false,"given":"Vera","family":"Weirauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9901-1727","authenticated-orcid":false,"given":"Achim","family":"Mortsiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-986X","authenticated-orcid":false,"given":"Sven","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"4","key":"R1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043407","article-title":"Digital transformation in healthcare: technology acceptance and its applications","volume":"20","author":"Stoumpos","journal-title":"Int J Environ Res Public Health"},{"key":"R2","unstructured":"Digital therapeutics (DTx). European Data Protection Supervisor. 2025. URL: https:\/\/www.edps.europa.eu\/press-publications\/publications\/techsonar\/digital-therapeutics-dtx [Accessed 24-08-2025]"},{"key":"R3","unstructured":"What is a DTx? Digital Therapeutics Alliance. 2025. URL: https:\/\/dtxalliance.org\/understanding-dtx\/what-is-a-dtx\/ [Accessed 24-08-2025]"},{"issue":"3","key":"R4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12599-023-00804-z","article-title":"Digital therapeutics (DTx)","volume":"65","author":"F\u00fcrstenau","journal-title":"Bus Inf Syst Eng"},{"key":"R5","unstructured":"ISO\/TR 11147:2023(en) health informatics \u2014 personalized digital health \u2014 digital therapeutics health software systems. International Organization for Standardization. URL: https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:tr:11147:ed-1:v1:en [Accessed 01-09-2025]"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00777-z","article-title":"Digital therapeutics from bench to bedside","volume":"6","author":"Wang","journal-title":"NPJ Digit Med"},{"key":"R7","unstructured":"Guidance on the review and approval of digital therapeutics (DTx) (revision). Ministry of Food and Drug Safety(Korea). 2020. URL: https:\/\/www.mfds.go.kr\/eng\/brd\/m_40\/view.do?seq=72624&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1 [Accessed 09-10-2025]"},{"key":"R8","unstructured":"DTx product categories. Digital Therapeutics Alliance. 2021. URL: https:\/\/dtxalliance.org\/wp-content\/uploads\/2021\/01\/DTA_FS_DTx-Product-Categories_010521.pdf [Accessed 18-02-2026]"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241308704","article-title":"Comparison of health technology assessments for digital therapeutics in Germany, the United Kingdom and France","volume":"11","author":"Arc\u00e0","journal-title":"Digit Health"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12793\/tcp.2019.27.1.6","article-title":"Digital therapeutics and clinical pharmacology","volume":"27","author":"Chung","journal-title":"Transl Clin Pharmacol"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10536","article-title":"Digital therapeutics in the clinic","volume":"8","author":"Phan","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01660-9","article-title":"Approved trends and product characteristics of digital therapeutics in four countries","volume":"8","author":"Liang","journal-title":"NPJ Digit Med"},{"issue":"43","key":"R13","doi-asserted-by":"publisher","first-page":"E1200","DOI":"10.1503\/cmaj.1095801","article-title":"How \u201cdigital therapeutics\u201d differ from traditional health and wellness apps","volume":"191","author":"Lougheed","journal-title":"CMAJ"},{"key":"R14","unstructured":"Wade B Abraham J Coder M et al. Classification of digital health technologies. Digital Therapeutics Alliance; 2023. URL: https:\/\/dtxalliance.org\/wp-content\/uploads\/2023\/06\/Guidance-to-Industry-Classification-of-Digital-Health-Technologies-2023Jun05.pdf [Accessed 04-09-2025]"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00410-x","article-title":"Assessing the quality of mobile applications in chronic disease management: a scoping review","volume":"4","author":"Agarwal","journal-title":"NPJ Digit Med"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1055\/a-1933-2779","article-title":"Digitale Gesundheitsinterventionen entwickeln, evaluieren und implementieren (Teil I) \u2013 Diskussionspapier der Arbeitsgruppe Digital Health des Deutschen Netzwerk Versorgungsforschung (DNVF)","volume":"85","author":"Kernebeck","journal-title":"Gesundheitswesen"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/a-1996-6141","article-title":"Erratum: Digitale Gesundheitsinterventionen entwickeln, evaluieren und implementieren (Teil I) \u2013 Diskussionspapier der Arbeitsgruppe Digital Health des Deutschen Netzwerk Versorgungsforschung (DNVF)","volume":"85","author":"Kernebeck","journal-title":"Gesundheitswesen"},{"issue":"5-6","key":"R18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/itit-2019-0019","article-title":"A design and evaluation framework for digital health interventions","volume":"61","author":"Kowatsch","journal-title":"it - Information Technology"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4258\/hir.2022.28.3.188","article-title":"Clinical evaluation of digital therapeutics: present and future","volume":"28","author":"Huh","journal-title":"Healthc Inform Res"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S489873","article-title":"Adoption of digital therapeutics in Europe","volume":"20","author":"Fassbender","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"R21","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2024.01004","article-title":"Digital therapeutics in Korea: current status, challenges, and future directions - a narrative review","volume":"42","author":"Shin","journal-title":"J Yeungnam Med Sci"},{"key":"R22","unstructured":"Das fast-track-verfahren f\u00fcr digitale gesundheitsanwendungen (diga) nach \u00a7 139e SGB v ein leitfaden f\u00fcr hersteller, leistungserbringer und anwender. Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM); 2020."},{"issue":"1","key":"R23","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09287-w","article-title":"Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis","volume":"23","author":"M\u00e4der","journal-title":"BMC Health Serv Res"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241249604","article-title":"Critical success factors for creating sustainable digital health applications: a systematic review of the German case","volume":"10","author":"Schramm","journal-title":"Digit Health"},{"key":"R25","unstructured":"DTx value assessment & integration guide version 2.0. Digital Therapeutics Alliance; 2022. URL: https:\/\/dtxalliance.org\/wp-content\/uploads\/2022\/05\/DTx-Value-Assessment-Guide_May-2022.pdf [Accessed 26-02-2026]"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Kim M Patrick K Nebeker C et al. The digital therapeutics real-world evidence framework: an approach for guiding evidence-based digital therapeutics design, development, testing, and monitoring (preprint). J Med Internet Res. Preprint posted online on 2023. [doi: 10.2196\/preprints.49208]","DOI":"10.2196\/preprints.49208"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.2196\/70955","article-title":"Digital therapeutics in China: comprehensive review","volume":"27","author":"Jiang","journal-title":"J Med Internet Res"},{"issue":"1","key":"R28","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01879-6","article-title":"Healthcare effects and evidence robustness of reimbursable digital health applications in Germany: a systematic review","volume":"8","author":"Sippli","journal-title":"NPJ Digit Med"},{"issue":"2","key":"R29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14020157","article-title":"Meta-analysis of studies on the effects of digital therapeutics","volume":"14","author":"Seo","journal-title":"J Pers Med"},{"key":"R30","unstructured":"Degun R Madaan P Ahmad S . The time is now for digital therapeutics. EY Parthenon; 2025. URL: https:\/\/www.ey.com\/content\/dam\/ey-unified-site\/ey-com\/en-uk\/industries\/life-sciences\/documents\/ey-the-time-is-now-for-digital-therapeutics.pdf [Accessed 13-10-2025]"},{"key":"R31","unstructured":"Setting the stage for a fit-for-purpose DTx evidentiary standard. Digital Therapeutics Alliance. 2022. URL: https:\/\/dtxalliance.org\/wp-content\/uploads\/2022\/12\/DTA-Clinical-Evidence-Paper_12.22.pdf [Accessed 08-09-2025]"},{"key":"R32","unstructured":"About COMET. COMET Initiative. 2025. URL: https:\/\/www.comet-initiative.org\/About [Accessed 15-09-2025]"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.2196\/62761","article-title":"Exploring participants\u2019 experiences of digital health interventions with qualitative methods: guidance for researchers","volume":"26","author":"Harrison Ginsberg","journal-title":"J Med Internet Res"},{"issue":"3","key":"R34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/22779779221134659","article-title":"Understanding and identifying \u2018themes\u2019 in qualitative case study research","volume":"11","author":"Mishra","journal-title":"South Asian Journal of Business and Management Cases"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1220160","article-title":"Healthcare professionals\u2019 and patients\u2019 assessments of listed mobile health apps in China: a qualitative study","volume":"11","author":"Liu","journal-title":"Front Public Health"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.2196\/48345","article-title":"Evidence of how physicians and their patients adopt mHealth apps in Germany: exploratory qualitative study","volume":"12","author":"Schroeder","journal-title":"JMIR Mhealth Uhealth"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.2196\/57786","article-title":"Dimensions and subcategories of digital maturity in general practice: qualitative study","volume":"26","author":"Neunaber","journal-title":"J Med Internet Res"},{"key":"R38","unstructured":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Oxford Academic. URL: https:\/\/academic.oup.com\/view-large\/27217733 [Accessed 03-10-2025]"},{"key":"R39","unstructured":"Finden Sie die passende digitale Gesundheitsanwendung. Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). 2025. URL: https:\/\/diga.bfarm.de\/de [Accessed 15-09-2025]"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Witzel A Reiter H . The Problem-Centred Interview: Principles and Practice. SAGE Publications Ltd; 2012. [doi: 10.4135\/9781446288030] ISBN: 978-1-4462-8803-0","DOI":"10.4135\/9781446288030"},{"issue":"3","key":"R41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/archdischild-2016-312117","article-title":"Core outcome sets","volume":"103","author":"Webbe","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Kuckartz U R\u00e4diker S . Qualitative Content Analysis: Methods, Practice and Software. SAGE Publications Ltd; 2023. [doi: 10.4135\/9781036212940] ISBN: 978-1-0362-1294-0","DOI":"10.4135\/9781036212940"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Kuckartz U R\u00e4diker S . Fokussierte Interviewanalyse mit MAXQDA: Schritt f\u00fcr Schritt 2 Aufl. Springer Fachmedien; 2024. [doi: 10.1007\/978-3-658-40212-9] ISBN: 978-3-658-40211-2","DOI":"10.1007\/978-3-658-40212-9"},{"key":"R44","unstructured":"Kuckartz U R\u00e4diker S . Qualitative inhaltsanalyse. In: Methoden, Praxis, Computerunterst\u00fctzung. Beltz Juventa; 2022:978-3. URL: https:\/\/content-select.com\/de\/portal\/media\/view\/5e623532-20b8-4f33-b19e-4a1db0dd2d03 [Accessed 19-08-2024] ISBN: 978-3-7799-5533-7"},{"issue":"1","key":"R45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1081\/COPD-200050641","article-title":"Minimal clinically important difference, clinical perspective: an opinion","volume":"2","author":"Rennard","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"1","key":"R46","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03843-5","article-title":"Effectiveness of a digital lifestyle management intervention (levidex) to improve quality of life in people with multiple sclerosis: results of a randomized controlled trial","volume":"24","author":"Meyer","journal-title":"BMC Neurol"},{"issue":"1","key":"R47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228100","article-title":"Effectiveness of a tailored, integrative internet intervention (deprexis) for depression: updated meta-analysis","volume":"15","author":"Twomey","journal-title":"PLoS One"},{"issue":"1","key":"R48","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04012-2","article-title":"Efficacy of digital therapeutics for perioperative management in patients with lung cancer: a randomized controlled trial","volume":"23","author":"Xu","journal-title":"BMC Med"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.2196\/83545","article-title":"Evaluating the efficacy of a digital therapeutic intervention for temporomandibular disorders: multicenter, randomized, sham-controlled trial","volume":"27","author":"Park","journal-title":"J Med Internet Res"},{"issue":"2","key":"R50","doi-asserted-by":"publisher","DOI":"10.2196\/35042","article-title":"Digital therapeutic care apps with decision-support interventions for people with low back pain in Germany: cost-effectiveness analysis","volume":"10","author":"Lewkowicz","journal-title":"JMIR Mhealth Uhealth"},{"issue":"1","key":"R51","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00489-x","article-title":"Cost-effectiveness analysis of digital therapeutics for home-based cardiac rehabilitation for patients with chronic heart failure: model development and data analysis","volume":"21","author":"Liu","journal-title":"Cost Eff Resour Alloc"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.2196\/73739","article-title":"Cost-utility analysis and value-based pricing of digital therapeutics for pulmonary rehabilitation in chronic respiratory disease: economic evaluation based on a randomized controlled trial","volume":"27","author":"Park","journal-title":"J Med Internet Res"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.2196\/47094","article-title":"Economic evaluation associated with clinical-grade mobile app-based digital therapeutic interventions: systematic review","volume":"25","author":"Sapanel","journal-title":"J Med Internet Res"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2026.1656614","article-title":"Perspectives on digital therapeutic prescribing: a qualitative study among German psychological psychotherapists","volume":"8","author":"Panitz","journal-title":"Front Digit Health"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.854665","article-title":"Success factors for scaling up the adoption of digital therapeutics towards the realization of P5 medicine","volume":"9","author":"Prodan","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"R56","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12656-2","article-title":"From awareness to integration: a qualitative interview study on the impact of digital therapeutics on physicians\u2019 practices in Germany","volume":"25","author":"Kendziorra","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"R57","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jtho.2020.05.005","article-title":"Principles of good clinical trial design","volume":"15","author":"An","journal-title":"J Thorac Oncol"},{"issue":"1","key":"R58","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1955-y","article-title":"The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials","volume":"18","author":"Clayton","journal-title":"Trials"},{"issue":"2","key":"R59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1747493017750923","article-title":"How to do high-quality clinical research 1: first steps","volume":"13","author":"Sandercock","journal-title":"Int J Stroke"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241302676","article-title":"Digital health applications in Germany: explorative pilot study on the challenges of approval from the perspective of manufacturers","volume":"10","author":"Ataiy","journal-title":"Digit Health"},{"issue":"12","key":"R61","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21121589","article-title":"Co-creation in the development of digital therapeutics: a narrative review","volume":"21","author":"Mimoso","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"R62","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/hex.13506","article-title":"Meaningful patient and public involvement in digital health innovation, implementation and evaluation: a systematic review","volume":"25","author":"Baines","journal-title":"Health Expect"},{"issue":"1","key":"R63","doi-asserted-by":"publisher","DOI":"10.2196\/55714","article-title":"Methods, indicators, and end-user involvement in the evaluation of digital health interventions for the public: scoping review","volume":"26","author":"Weirauch","journal-title":"J Med Internet Res"},{"issue":"2","key":"R64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00103-019-03079-6","article-title":"Implementierung und partizipative Gestaltung digitaler Gesundheitsinterventionen","volume":"63","author":"Hochmuth","journal-title":"Bundesgesundheitsbl"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.2196\/71600","article-title":"Integrating patient perspectives into the digital health technology readiness framework: Delphi study","volume":"27","author":"de la Torre","journal-title":"J Med Internet Res"},{"issue":"1","key":"R66","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01385-1","article-title":"An umbrella review on how digital health intervention co-design is conducted and described","volume":"7","author":"Kilfoy","journal-title":"NPJ Digit Med"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100486","article-title":"Choosing primary endpoints for clinical trials of health care interventions","volume":"16","author":"McLeod","journal-title":"Contemp Clin Trials Commun"},{"issue":"16","key":"R68","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36115","article-title":"A comprehensive survey of the clinical trial landscape on digital therapeutics","volume":"10","author":"Yao","journal-title":"Heliyon"},{"issue":"1","key":"R69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s43441-022-00442-9","article-title":"Comprehensive analysis of clinical studies and regulations of therapeutic applications in the United States and Japan","volume":"57","author":"Ono","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"R70","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05891-5","article-title":"A survey of knowledge, perceptions and use of core outcome sets among clinical trialists","volume":"22","author":"Bellucci","journal-title":"Trials"},{"issue":"Suppl 3","key":"R71","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET handbook: version 1.0","volume":"18","author":"Williamson","journal-title":"Trials"},{"issue":"10","key":"R72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002148","article-title":"Core Outcome Set-STAndards for Reporting: the COS-STAR statement","volume":"13","author":"Kirkham","journal-title":"PLoS Med"},{"issue":"12","key":"R73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225980","article-title":"Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research","volume":"14","author":"Gargon","journal-title":"PLoS One"},{"issue":"1","key":"R74","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-132","article-title":"Developing core outcome sets for clinical trials: issues to consider","volume":"13","author":"Williamson","journal-title":"Trials"},{"issue":"Suppl","key":"R75","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.3349\/ymj.2022.63.S56","article-title":"Survey for government policies regarding strategies for the commercialization and globalization of digital therapeutics","volume":"63","author":"Kim","journal-title":"Yonsei Med J"}],"container-title":["JMIR Formative Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:41:29Z","timestamp":1792075289000},"score":1,"resource":{"primary":{"URL":"https:\/\/formative.jmir.org\/2026\/1\/e86437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":75,"URL":"https:\/\/doi.org\/10.2196\/86437","relation":{},"ISSN":["2561-326X"],"issn-type":[{"value":"2561-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"v10i4e86437"}}